Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749323 | 0.88 | PRCP (0.51) | PRCPALDH1A1SMN1; SMN2 | |
| SCHEMBL14749330 | 0.87 | PRCP (0.57) | PRCPALDH1A1SMN1; SMN2GFEREGFR | |
| SCHEMBL14749328 | 0.86 | PRCP (0.61) | PRCPALDH1A1SMN1; SMN2PROKR1CSNK1D | |
| SCHEMBL14749332 | 0.85 | PRCP (0.54) | PRCPALDH1A1SMN1; SMN2EGFRPROKR1 | |
| SCHEMBL14736875 | 0.85 | PRCP (0.59) | PRCPPROKR1NAMPTGRM5 | |
| SCHEMBL14749364 | 0.85 | PRCP (0.55) | PRCPALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL14749336 | 0.85 | PRCP (0.55) | PRCPALDH1A1SMN1; SMN2NAMPT | |
| SCHEMBL14749343 | 0.85 | PRCP (0.56) | PRCPALDH1A1HRH3GRM5 | |
| SCHEMBL14749316 | 0.84 | PRCP (0.57) | PRCPALDH1A1SMN1; SMN2 | |
| SCHEMBL14749342 | 0.84 | PRCP (0.53) | PRCPALDH1A1SMN1; SMN2GFERPROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885ALDH1A1 661/4885SMN1; SMN2 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.